Form 4: Labcorp Director Receives Restricted Stock Unit Grant
Insider Transaction Report
Labcorp Holdings Inc. Director Kerrii B. Anderson was granted 773 Restricted Stock Units, vesting in February 2027.
Summary
- Kerrii B. Anderson, a Director of Labcorp Holdings Inc. (LH), acquired 773 Restricted Stock Units (RSUs).
- Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
- The RSUs were acquired on February 10, 2026, with a price of $0, typical for such grants.
- These Restricted Stock Units are scheduled to vest fully on February 10, 2027.
- Following this transaction, Kerrii B. Anderson beneficially owns an aggregate of 1,670 Restricted Stock Units.
- A Power of Attorney was granted by Kerrii B. Anderson to Kathryn W. Kyle on December 9, 2025, to handle Section 16 filings on her behalf.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It reports a routine insider transaction related to director compensation and does not indicate any significant operational or financial changes for Labcorp Holdings Inc.
Positives
- The grant of Restricted Stock Units aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
Future Outlook
N/A
Management Comments
- "/s/ Kathryn W. Kyle Attorney-in-Fact for Kerrii B. Anderson" (signature on Form 4).
Industry Context
StockSavvy.ai notes that equity grants, such as Restricted Stock Units, are a common form of executive and director compensation across various industries, including healthcare and diagnostics, to incentivize long-term performance and align leadership interests with shareholder value.
Comparison to Industry Standards
- The grant of Restricted Stock Units to a director is a standard practice in corporate compensation structures, comparable to similar grants observed at peer companies within the healthcare and diagnostics sector, such as Quest Diagnostics (DGX) or DaVita Inc. (DVA).
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Administrative Delegation | Kerrii B. Anderson granted a Power of Attorney to Kathryn W. Kyle to execute and file Section 16 forms (Forms 3, 4, and 5) on her behalf with the SEC and stock exchanges. | December 9, 2025 | Streamlines compliance with SEC reporting requirements for insider transactions, ensuring timely and accurate filings by delegating the administrative task to an attorney-in-fact. |
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's long-term interests with shareholder value, as the compensation's ultimate value depends on the company's stock performance.
- Management/Directors: The grant represents a component of the director's compensation package, incentivizing continued service and performance.
Next Steps
- The 773 Restricted Stock Units are expected to vest fully on February 10, 2027.
Key Dates
| Date | Description |
|---|---|
| December 9, 2025 | Kerrii B. Anderson executed a Power of Attorney appointing Kathryn W. Kyle as attorney-in-fact for Section 16 filings. |
| February 10, 2026 | Date of acquisition of 773 Restricted Stock Units by Kerrii B. Anderson. |
| February 12, 2026 | Date the Form 4 was signed by the attorney-in-fact. |
| February 10, 2027 | Date when the 773 Restricted Stock Units are scheduled to vest fully. |
Keywords
Labcorp Holdings Inc., LH, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.